Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dupilumab Therapy for EGIDs
Sponsor: Children's Hospital of Fudan University
Summary
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
Official title: Dupilumab Therapy for Refractory Eosinophilic Gastrointestinal Disorders in Children
Key Details
Gender
All
Age Range
1 Year - 18 Years
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2025-01-01
Completion Date
2027-12-01
Last Updated
2025-12-02
Healthy Volunteers
No
Interventions
Dupilumab - Standard Dose
Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.
subcutaneous injection
Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.
Locations (1)
201102
Shanghai, China